Skip to main contentSkip to navigationSkip to search

Press release

Camurus to present at SEB Biotech Seminar in Stockholm

18 January 2019

Lund, Sweden — 18 January 2019 — Camurus (NASDAQ STO: CAMX) today announced that that the Company will present at the SEB Biotech Seminar in Stockholm 24 January at 8:30 am. Fredrik Tiberg, President and CEO, will give an update on the company's activities, including the ongoing launch of Buvidal® weekly and monthly depots for the treatment of opioid dependence.

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

Fredrik Joabsson, VP Business Development
Tel. +46 (0)70 776 17 37

This information was submitted for publication at 10.00 am CET on 18 January 2019.

TypeError: Cannot read properties of undefined (reading 'url')